Bacterial urinary tract infection in cats with ckd. Feline rhinitis and tracheobronchitis. Surface and superficial pyoderma

Size: px
Start display at page:

Download "Bacterial urinary tract infection in cats with ckd. Feline rhinitis and tracheobronchitis. Surface and superficial pyoderma"

Transcription

1 DISEASE FACT SHEETS

2 CONTENTS Canine cystitis Bacterial urinary tract infection in cats with ckd Metritis and pyometra Mastitis Canine rhinitis Canine tracheobronchitis Feline rhinitis and tracheobronchitis Surface and superficial pyoderma Deep pyoderma Otitis externa and media Conjunctivitis and keratitis Osteomyelitis Wound infections and abscesses Post operative infections Prevention of surgical complications (including peritonitis and abscesses)

3 CANINE CYSTITIS Therapeutic approach Urinary cytology - Empirical treatment Bacilli (assume) Escherichia coli Amoxicillin+clavulanate, trimethoprim sulfonamides Cocci (assume) Staphylococcus spp. Amoxicillin, trimethoprim sulfonamides Culture and sensitivity Escherichia coli Amoxicillin ± clavulanate, trimethoprim sulfonamides Staphylococcus spp. Amoxicillin ± clavulanate, trimethoprim sulfonamides Cefalexin, marbofloxacin, enrofloxacin, cefovecin, nitrofurantoin Cefalexin, marbofloxacin, enrofloxacin, cefovecin, nitrofurantoin Pradofloxacin, gentamicin Pradofloxacin, gentamicin

4 CANINE CYSTITIS Treatment recommendations First choice antibiotic Escherichia coli Staphylococcus spp. Amoxicillin + clavulanate Trimethoprim sulfonamides a Amoxicillin Trimethoprim sulfonamides a mg/kg/12h PO 1 mg/kg/12h PO 1 mg/kg/8-12h PO 1 mg/kg/12h PO 10-1 mg/kg/2 SC in 7 dogs days (uncomplicated cystitis) 28 days (complicated cystitis) Second choice antibiotic (with culture and sensitivity testing and only if first choice is not an option) Amoxicillin ± clavulanate 10-2 mg/kg/12h PO Escherichia coli Staphylococcus spp. Cefalexin Marbofloxacin b Enrofloxacin b Nitrofurantoin d Cefovecin c 1-30 mg/kg/12h PO 2 mg/kg/2h PO mg/kg/2h PO.- mg/kg/8h PO 8 mg/kg SC for 1d (for complicated UTIs repeat dose after 1d) 7 days (uncomplicated cystitis) 28 days (complicated cystitis) a Avoid use longer than 3 weeks as risk of keratoconjunctivitis sicca (KCS) and nephrotoxicity. Schirmer tear testing is recommended if use > 3 weeks6. b Avoid use in growing dogs of large breeds. c Cefovecin is a third generation cephalosporin and therefore a last resort antibiotic. It should only be used if sensitivity testing indicates that other antibiotics would be ineffective or if oral administration of medication is not possible. d Nitrofurantoin is a human preparation useful in multi-drug resistant UTIs; use should be guided by culture and sensitivity testing and by cascade guidelines.

5 BACTERIAL URINARY TRACT INFECTION IN CATS WITH CKD Therapeutic approach Urine dipstick, cytology Gram-negative rod (suspicion of Escherichia coli ) Culture and sensitivity Empirical treatment while awaiting results Amoxicillin ± clavulanate, trimethoprim sulfonamides Gram-positive cocci (suspicion of Enterococcus spp.) Amoxicillin Results of culture and sensitivity De-escalate if possible, adapt if necessary E. coli Amoxicillin ± clavulanate, trimethoprim sulfonamides Enterococcus spp. Amoxicillin Cefalexin, marbofloxacin, enrofloxacin, cefovecin Amoxicillin + clavulanate, marbofloxacin, enrofloxacin Pradofloxacin Pradofloxacin

6 Culture and sensitivity testing should be performed to select the most appropriate antibiotic and hence reduce the potential for further irreversible damage to the kidney. First choice antibiotic Escherichia coli BACTERIAL URINARY TRACT INFECTION IN CATS WITH CKD Treatment recommendations Amoxicillin Amoxicillin + clavulanate Trimethoprim sulfonamides a 10-2 mg/kg/8h IV 10-1 mg/kg/8h PO 10 mg/kg/8h IV mg/kg/8-12h PO 1 mg/kg/12h PO 10-1 mg/kg/2 SC in dogs 28 days complicated UTI Enterococcus spp. Amoxicillin 10-2 mg/kg/8h IV 10-1 mg/kg/8h PO Second choice antibiotic (with culture and sensitivity testing) Cefalexin Marbofloxacin Consider adjustment for Stage 3& IRIS 1-30 mg/kg/12h PO 2 mg/kg/2h IV, SC, PO 10-1 mg/kg/2 SC in dogs Escherichia coli Enterococcus spp. Enrofloxacin b Cefovecin c Amoxicillin + clavulanate f Marbofloxacin mg/kg/2h SC, PO 8 mg/kg single dose SC (1d) 20 mg/kg/8h IV mg/kg/8-12h PO 2 mg/kg/2h IV, SC, PO 28 days complicated UTI Enrofloxacin b mg/kg/2h SC, PO a Avoid use longer than 3 weeks as risk of keratoconjunctivitis sicca (KCS) and nephrotoxicity. Schirmer tear testing is recommended if use > 3 weeks7. b In cats, use of enrofloxacin has been associated with a risk of retinal toxicity. Do not exceed mg/kg. c Cefovecin is a third generation cephalosporin and therefore a last resort antibiotic. It should only be used if sensitivity testing indicates that other antibiotics would be ineffective or if oral administration of medication is not possible. f Use of a ß-lactamase inhibitor (clavulanate) is not usually required for treatment of Enterococcus spp. infections hence amoxicillin+clavulanate is designated as 2nd choice, however its use may be a compromise to achieve patient/owner compliance.

7 METRITIS AND PYOMETRA Therapeutic approach Culture and sensitivity Empirical treatment while awaiting results Amoxicillin ± clavulanate, trimethoprim sulfonamides Results of culture and sensitivity De-escalate if possible, adapt if necessary Escherichia coli Amoxicillin, trimethoprim sulfonamides Staphylococcus/Streptococcus Amoxicillin, trimethoprim sulfonamides Amoxicillin + clavulanate, cefalexin, marbofloxacin, enrofloxacin Amoxicillin + clavulanate, cefalexin, marbofloxacin, enrofloxacin

8 METRITIS AND PYOMETRA Treatment recommendations First choice antibiotic Escherichia coli Staphylococcus spp. Streptococcus spp. Amoxicillin ± clavulanate Trimethoprim sulfonamides a 10-2 mg/kg/12h PO, SC, IV 1 mg/kg/12h PO, IV 2-3 weeks Second choice antibiotic (with culture and sensitivity testing) Escherichia coli Staphylococcus spp. Streptococcus spp. Cefalexin Marbofloxacin b Enrofloxacin b,c 1-30 mg/kg/12h PO 2 mg/kg/2h PO, SC, IV mg/kg/2h PO, SC 10-1 mg/kg/2 SC in dogs 2-3 weeks a Avoid use longer than 3 weeks as risk of keratoconjunctivitis sicca (KCS) and nephrotoxicity. Schirmer tear testing is recommended if use > 3 weeks3. b Avoid use in growing dogs of large breeds. c In cats, use of enrofloxacin has been associated with a risk of retinal toxicity. Do not exceed mg/kg.

9 MASTITIS Therapeutic approach Culture and sensitivity Escherichia coli Amoxicillin ± clavulanate, trimethoprim sulfonamides Staphylococcus Amoxicillin ± clavulanate, trimethoprim sulfonamides Cefalexin, marbofloxacin, enrofloxacin Cefalexin, marbofloxacin, enrofloxacin

10 MASTITIS Treatment recommendations In nursing bitches and queens, only amoxicillin ± clavulanate and cefalexin should be used. First choice antibiotic Escherichia coli Staphylococcus spp. Streptococcus spp. Amoxicillin ± clavulanate Trimethoprim sulfonamides a 10-2 mg/kg/12h PO, SC, IV mg/kg/12h PO, SC, IV 10-1 days Second choice antibiotic (with culture and sensitivity testing) Escherichia coli Staphylococcus spp. Streptococcus spp. Cefalexin Marbofloxacin b Enrofloxacin b,c 1-30 mg/kg/12h PO 2 mg/kg/2h PO, SC, IV mg/kg/2h PO, SC 10-1 mg/kg/2 SC in dogs 10-1 days a Avoid use longer than 3 weeks as risk of keratoconjunctivitis sicca (KCS) and nephrotoxicity. Schirmer tear testing is recommended if use > 3 weeks2. b Avoid use in growing dogs of large breeds. c In cats, use of enrofloxacin has been associated with a risk of retinal toxicity. Do not exceed mg/kg.

11 CANINE RHINITIS Therapeutic approach Empirical treatment ONLY IF antibiotherapy is necessary Amoxicillin+clavulanate, doxycycline Marbofloxacin, enrofloxacin If insufficient improvement, consider culture and AST of nasal biopsy or nasal flush

12 CANINE RHINITIS Treatment recommendations Culture and sensitivity testing is not justified in most cases of canine nasal disease, but antibiotic treatment of secondary bacterial infections can be necessary. First choice antibiotic Culture not recommended Amoxicillin + clavulanate Doxycycline mg/kg/12h PO, SC, IV mg/kg/12h or 10 mg/kg/2h PO 2-3 weeks Second choice antibiotic (with culture and sensitivity testing) Culture not recommended Marbofloxacin a Enrofloxacin a 2 mg/kg/2h PO, SC mg/kg/2h PO, SC 10-1 mg/kg/2 SC in dogs 2-3 weeks a Avoid use in growing dogs of large breeds.

13 CANINE TRACHEOBRONCHITIS Therapeutic approach Empirical treatment ONLY IF antibiotherapy is necessary Amoxicillin+clavulanate, doxycycline Marbofloxacin, enrofloxacin If insufficient improvement, perform tracheal or bronchial lavage, cytology and C&AST

14 CANINE TRACHEOBRONCHITIS Treatment recommendations First choice antibiotic Bordetella bronchiseptica Streptococcus spp. Amoxicillin + clavulanate Doxycycline Amoxicillin mg/kg/12h PO, SC, IV 10 mg/kg/2h PO 10-1 mg/kg/12h PO 7-10 days, until clinical and radiographic cure Second choice antibiotic (with culture and sensitivity testing) Bordetella bronchiseptica Trimethoprim sulfonamides a Marbofloxacin b 1-30 mg/kg/12h PO, IV 2 mg/kg/2h PO, SC Streptococcus spp. Enrofloxacin b Cefalexin Doxycycline Marbofloxacin b mg/kg/2h PO, SC 1-30 mg/kg/12h PO 10 mg/kg/2h PO 2 mg/kg/2h PO, SC 7-10 days, until clinical and radiographic cure Enrofloxacin b mg/kg/2h PO, SC a Avoid use longer than 3 weeks as risk of keratoconjunctivitis sicca (KCS) and nephrotoxicity. Schirmer tear testing is recommended if use > 3 weeks3. b Avoid use in growing dogs of large breeds.

15 FELINE RHINITIS AND TRACHEOBRONCHITIS Therapeutic approach Yes Upper respiratory tract signs Since < 10 days? No Acute disease Chronic disease Address any underlying illness, e.g. viral infection Supportive treatment usually suffices Empirical treatment if severe clinical signs (mucopurulent discharge, fever, lethargy, inappetence) Doxycycline If no improvement Diagnostic tests*: cytology and C&AST Bordetella bronchiseptica Doxycycline Pasteurella spp. Doxycycline Mycoplasma spp. Doxycycline Amoxicillin + clavulanate, marbofloxacin, enrofloxacin Amoxicillin Marbofloxacin, enrofloxacin Pradofloxacin Amoxicillin + clavulanate, marbofloxacin, enrofloxacin, pradofloxacin Clindamycin, pradofloxacin

16 FELINE RHINITIS AND TRACHEOBRONCHITIS Treatment recommendations First choice antibiotic (empirical or with culture and sensitivity testing) Acute rhinitis & tracheobronchitis with Bordetella bronchiseptica, Mycoplasma spp. or secondary bacterial infection: 7-10 days; Chlamydia felis: weeks Bordetella bronchiseptica, Mycoplasma spp., (Chlamydia felis) Pasteurella spp. Doxycycline c 10 mg/kg/2h PO Chronic rhinitis 6 weeks d Chronic bronchitis/asthma with Mycoplasma spp. infection: 6 weeks d Chronic bronchitis with Pasteurella spp. infection: 2- weeks Second choice antibiotic (with culture and sensitivity testing) Bordetella bronchiseptica, Mycoplasma spp. Marbofloxacin Enrofloxacin a 2 mg/kg/2h PO mg/kg/2h PO Acute rhinitis & tracheobronchitis with Bordetella bronchiseptica or Mycoplasma spp. infection: 7-10 days Chronic bronchitis/asthma with Mycoplasma spp. infection: 6 weeks d Pasteurella spp. Amoxicillin Amoxicillin + clavulanate e 10-2 mg/kg/8h IV, PO 20 mg/kg/8h IV mg/kg/8-12h PO Acute rhinitis & tracheobronchitis 7-10 days; Chronic rhinitis 6 weeks d Chronic bronchitis with Pasteurella spp. infection: 2- weeks a In cats, use of enrofloxacin has been associated with a risk of retinal toxicity. Do not exceed mg/kg. b Pradofloxacin is a last resort choice due to its very extended spectrum of activity and should only be used if a narrower spectrum antibiotic cannot be used (based on sensitivity testing results). c Doxycycline hyclate/hydrochloride tablets must be followed with water or food to ensure passage into the stomach to prevent development of oesophagitis and/or strictures3. d Note: initial treatment course for chronic rhinitis is prolonged (e.g. 6 weeks), subsequent flare-ups may be managed with shorter courses e.g. 2- weeks. e Use of a ß-lactamase inhibitor (clavulanate) is not usually required for treatment of Pasteurella spp. infections hence amoxicillin+clavulanate is designated as 3rd choice earlier, however use may be a compromise to achieve patient/owner compliance.

17 SURFACE AND SUPERFICIAL PYODERMA Therapeutic approach Localised lesions Widespread lesions Cytology for diagnosis Surface pyoderma: Bacterial overgrowth ± Malassezia without neutrophils Superficial pyoderma: Presence of neutrophils with intracellular bacteria Daily disinfectant gel, spray, creams mousse, wipes Shampoo twice weekly + daily disinfectant spray, mousse, wipes Treat ly until clinically cured and cytology is negative (usually 2-3 weeks) In case of treatment failure, consider fucidic acid or systemic antibiotics (see Deep pyoderma) In case of treatment failure, consider systemic antibiotics (see Deep pyoderma)

18 SURFACE AND SUPERFICIAL PYODERMA Treatment recommendations Antiseptics that Antibiotics should preferably not be used in cases of surface and superficial pyoderma. Antiseptics should be used instead. Antiseptic that Chlorhexidine 2-% shampoo Chlorh.* wipes, mousse, spray Benzoyl peroxide 2.% Ethyl lactate 10% Triclosan Hypochlorous acid Bleach % Benzalconium chloride Medical honey Fusidic acid Mupirocin * Chlorhexidine In vitro sensitivity 3 3 Tissue distribution Treatment choice Limited clinical evidence No clinical evidence No residual efficacy, use daily Daily soak No clinical evidence Do not mix with other s For localized lesions only Not licensed for animal use Sensitivity and distribution 1 = nil 2 = weak 3 = average = good = excellent Treatment choice 1 st line 2 nd line Last resort Excluded for this indication

19 DEEP PYODERMA Therapeutic approach Therapeutic approach for deep pyoderma and for superficial pyoderma that is unresponsive to treatment. Cytology for diagnosis - presence of intracellular bacteria (pyoderma) - identification of cocci and/or rods Empirical treatment only in case of: - superficial pyoderma with failed treatment - first occurence of superficial coccal infections Culture & AST in case of: - deep pyoderma - presence of rods - relapsing pyoderma (cocci and rods) - failure of empirical treatment - previous antibiotic treatment Amoxicillin + clavulanate, cefalexin, cefadroxil, clindamycin Amoxicillin + clavulanate cefalexin, cefadroxil, clindamycin Enrofloxacin, marbofloxacin, cefovecin In case of treatment failure, perform culture and AST Pradofloxacin, rifampicin, chloramphenicol, fosfomycin, aminoglycosides Treat until one week beyond clinical cure for superficial pyoderma and two weeks beyond clinical cure for deep pyoderma (usually at least 3- weeks) a Cefovecin is a third generation cephalosporin and therefore a last resort antibiotic. It should only be used if sensitivity testing indicates that other antibiotics would be ineffective or if oral administration of medication is not possible. b Avoid use longer than 3 weeks as risk of keratoconjunctivitis sicca (KCS) and nephrotoxicity. Schirmer tear testing is recommended if use > 3 weeks 28. c Avoid use in growing dogs of large breeds. d In cats, use of enrofloxacin has been associated with a risk of retinal toxicity. Do not exceed mg/kg. e Pradofloxacin is a last resort choice due to its very extended spectrum of activity and should only be used if a narrower spectrum antibiotic cannot be used (based on sensitivity testing results). f Hepatotoxic, refer to National regulations regarding use. g Aminoglycosides are potentially ototoxic and nephrotoxic; do not use in patients with renal dysfunction (see

20 DEEP PYODERMA Treatment recommendations First choice antibiotic Meticillin sensitive Staphylococcus spp. Amoxicillin+clavulanate mg/kg/12h PO Cefalexin Cefadroxil Clindamycin 1-30 mg/kg/12h PO 1-30 mg/kg/12h PO or 30-0 mg/kg/2h PO.-11 mg/kg/12h PO 10-1 mg/kg/2 SC in dogs 1 week beyond cure for superficial pyoderma, 2 weeks beyond cure for deep pyoderma. Second choice antibiotic (following culture and sensitivity testing): only if bacteria are resistant to the first-choice antibiotics Trimethoprim sulfonamides b Marbofloxacin c 1-30 mg/kg/12h PO 2 mg/kg/2h PO 10-1 mg/kg/2 SC in dogs Meticillin-resistant, multidrug-resistant Staphylococcus spp. E. coli Ps. aeruginosa Enrofloxacin c,d Doxycycline Minocycline Rifampin f Chloramphenicol Fosfomycin Gentamicin g Amikacin g Cefovecin a mg/kg/2h PO 10 mg/kg/2 h PO 20 mg/kg/12h PO -10 mg/kg/12h PO 0 mg/kg/8h PO 0 mg/kg/12h PO 10-1 mg/kg/2h SC in dogs -8 mg/kg/2h SC in cats 1-30 mg/kg/2h SC in dogs 10-1 mg/kg/2h SC in cats 8 mg/kg single dose SC (1d) 1 week beyond cure for superficial pyoderma, 2 weeks beyond cure for deep pyoderma. Minimum 2 injections, suitable only in case of compliance problems

21 OTITIS EXTERNA AND MEDIA Therapeutic approach MANAGEMENT OF OTITIS Identification and correction of underlying cause Evaluation of tympanic membrane and middle ear Tympanic membrane intact, no evidence of otitis media Ruptured tympanic membrane and/or evidence of otitis media Cytology Culture and sensitivity Treat TOPICALLY until cytological testing is negative. Flush daily with disinfectant, at least one hour prior to applying the TOPICAL antibiotic. SYSTEMIC antibiotic (see Deep pyoderma, p.138) for 3-6 weeks Yeasts Rods (bacilli) Cocci Antifungals Polymixin B, silver sulfadiazine Neomycin, fusidic acid, framycetin, florfenicol Gentamicin, marbofloxacin, enrofloxacin Pradofloxacin, ticarcillin, amikacin Gentamicin, marbofloxacin, enrofloxacin Pradofloxacin, amikacin

22 OTITIS EXTERNA AND MEDIA Treatment recommendations Topical antibiotics are only to be used if there is no evidence of a ruptured tympanic membrane and/or otitis media. Systemic antibiotics should be used only following bacterial culture and susceptibility testing in case of a ruptured tympanic membrane and/or otitis media. In this case refer to antibiotics described in Deep pyoderma. Pathogen 1: Staphylococcus spp. Neomycin Fusidic acid Framycetin Florfenicol Gentamicin a Marbofloxacin / Enrofloxacin Pradofloxacin Amikacin a a Do not mix with acidic cleaners. In vitro sensitivity Tissue distribution ; Inactivated in pus Treatment choice Sensitivity and distribution 1 = nil 2 = weak 3 = average = good = excellent Treatment choice Pathogen 2: Pseudomonas aeruginosa 1 st line Polymixin B Silver sulfadiazine Gentamicin a Marbofloxacin / Enrofloxacin Pradofloxacin Amikacin a Ticarcillin Ceftazidime a Do not mix with acidic cleaners. In vitro sensitivity Tissue distribution ; Inactivated in pus Treatment choice 2 nd line Last resort Excluded for this indication

23 CONJUNCTIVITIS AND KERATITIS Therapeutic approach Dogs Corneal smear (cytology ± culture) Escherichia coli (Gram-negative rod) Staphylococcus/ Streptococcus spp. (Gram-positive cocci) Neomycin + bacitracin + polymyxin B Neomycin + bacitracin + polymyxin B, Fucidic acid Chloramphenicol Chloramphenicol Cats Corneal smear (cytology ± culture)* Chlamydophila Doxycycline Staphylococcus/ Streptococcus spp. (Gram-positive cocci) Neomycin + bacitracin + polymyxin B, Fucidic acid Amoxicillin + clavulanate Chloramphenicol * Mycoplasma spp. cannot be diagnosed using a corneal smear or the usual culture techniques. For this pathogen, PCR is the gold standard diagnostic test.

24 CONJUNCTIVITIS AND KERATITIS Treatment recommendations First choice antibiotic (whilst waiting for culture and sensitivity testing) Staphylococcus spp. Streptococcus spp. Fusidic acid (eye drops/ointment) Neomycin - bacitracin polymyxin (eye drops) 1-2 times/day -6 times/day 8-10 days Chlamydophila spp. Doxycycline (oral) 10 mg/kg/2h 30 days Mycoplasma spp.* Doxycycline (oral) 10 mg/kg/2h 2- weeks Second choice antibiotic (following culture and sensitivity testing) Staphylococcus spp. Streptococcus spp. Chloramphenicol (eye drops) 2-3 times/day 8-10 days Mycoplasma spp.* Chlamydophila spp. Amoxicillin + clavulanate (oral) mg/kg/12h PO 30 days 9 * Mycoplasma spp. cannot be diagnosed using a corneal smear or the usual culture techniques. For this pathogen, PCR is the gold standard diagnostic test.

25 OSTEOMYELITIS Therapeutic approach Culture and sensitivity Empirical treatment while awaiting results Implant removal if possible Amoxicillin+clavulanate, cefalexin, cefadroxil, clindamycin Results of culture and sensitivity De-escalate if possible, adapt if necessary Implant removal if possible Placement of antibiotic-impregnated implants if needed Amoxicillin ± clavulanate, cefalexin, cefadroxil, clindamycin Enrofloxacin, marbofloxacin Gentamicin, cefovecin

26 OSTEOMYELITIS Treatment recommendations n Non-antibiotic treatment: remove infected implants, review unstable fixation, curettage of sequestra/abscesses. n Local antibiotic treatment: placement of antibiotic-impregnated implants. First choice antibiotic Cefalexin 1-30 mg/kg/12h PO Staphylococcus spp. Streptococcus spp. E.coli Cefadroxil Amoxicillin + clavulanate mg/kg/12h PO mg/kg/8-12h PO Up to 2 weeks beyond clinical and radiographic resolution of the infection. Clindamycin 11 mg/kg/12h PO Second choice antibiotic (with culture and sensitivity testing) Staphylococcus spp. Streptococcus spp. E.coli Marbofloxacin a Enrofloxacin a,b Gentamicin d Cefovecin c 2 mg/kg/2h PO mg/kg/2h PO 7 mg/kg/2h-iv Local beads e 8 mg/kg single dose SC (1 days) Up to 2 weeks beyond clinical and radiographic resolution of the infection. Up to 2 weeks beyond clinical and radiographic resolution of the infection. (1 injection per 1 days) a Avoid use in growing dogs of large breeds. b In cats, use of enrofloxacin has been associated with a risk of retinal toxicity. Do not exceed mg/kg. c Cefovecin is a third generation cephalosporin and therefore a last resort antibiotic. It should only be used if sensitivity testing indicates that other antibiotics would be ineffective or if oral administration of medication is not possible. d Aminoglycosides are potentially ototoxic and nephrotoxic; do not use in patients with renal dysfunction (see e Unsuitable for long-term treatment (potentially nephrotoxic, systemic diffusion possible) - see

27 WOUND INFECTIONS AND ABSCESSES Therapeutic approach Abscesses: No antibiotic unless fever or severe systemic infection. Surgical debridement, abscess drainage and lavage usually suffice. Clean (contaminated) Direct closure Amoxicillin+clavulanate, cefalexin, cefadroxil (- days) If fully granulated, open management No need for antibiotics Infected Culture and sensitivity Empirical treatment while awaiting results Amoxicillin+clavulanate, cefalexin, cefadroxil Results of culture and sensitivity De-escalate if possible, adapt if necessary Amoxicillin ± clavulanate, cefalexin, cefadroxil, clindamycin, metronidazole Enrofloxacin, marbofloxacin Cefovecin, pradofloxacin

28 WOUND INFECTIONS AND ABSCESSES Treatment recommendations First choice antibiotic Pasteurella multocida (cats) Staphylococcus Escherichia coli Pasteurella Anaerobes Anaerobes Amoxicillin Amoxicillin + clavulanate Cefalexin Clindamycin mg/kg/12h mg/kg/12h 1-30 mg/kg/12h.-11 mg/kg/12h Clean: - days if closure. Dirty or deep: until establishment of healthy granulated tissue, usually 7-10 days. Second choice antibiotic (with culture and sensitivity testing) Pasteurella Staphylococcus Pseudomonas Marbofloxacin a Enrofloxacin a,b 2 mg/kg/2h mg/kg/2h (Up to mg/kg/12 h for resistant Pseudomonas) Clean: - days if closure. Dirty or deep: until establishment of healthy granulated tissue, usually 7-10 days. a Avoid use in growing dogs of large breeds. b In cats, use of enrofloxacin has been associated with a risk of retinal toxicity. Do not exceed mg/kg.

29 POST OPERATIVE INFECTIONS Therapeutic approach Culture and sensitivity Empirical treatment while awaiting results Amoxicillin+clavulanate, cefalexin, clindamycin Results of culture and sensitivity De-escalate if possible, adapt if necessary Staphylococcus Amoxicillin+clavulanate, cefalexin, clindamycin Gram-negative Amoxicillin+clavulanate Enrofloxacin, marbofloxacin Cefalexin, clindamycin, enrofloxacin, marbofloxacin Cefovecin, aminoglycosides Cefovecin, aminoglycosides

30 POST OPERATIVE INFECTIONS Treatment recommendations n The antibiotic should be available in an IV formulation for acute and potentially lifethreatening infection (see below). Amoxicillin+clavulanate and pradofloxacin have better anti-anaerobic activity than other ß-lactams and fluoroquinolones, but metronidazole can be considered where there is specific concern over anaerobic contamination. First choice antibiotic Amoxicillin + clavulanate mg/kg/12h Gram-positive (Staphylococcus) Cefalexin Clindamycin 1-30 mg/kg/12h.-11 mg/kg/12h Until evidence of healing Gram-negative Amoxicillin + clavulanate mg/kg/12h Second choice antibiotic (after culture and sensitivity testing) Marbofloxacin a 2 mg/kg/2h Gram-positive (Staphylococcus) or Gram-negative Enrofloxacin a,b Cefovecin c Gentamicin d mg/kg/2h 8 mg/kg/1j-sc 8 mg/kg/2h Until evidence of healing Amikacin d 10-1 mg/kg/2h a Avoid use in growing dogs of large breeds. b In cats, use of enrofloxacin has been associated with a risk of retinal toxicity. Do not exceed mg/kg. c Cefovecin is a third generation cephalosporin and therefore a last resort antibiotic. It should only be used if sensitivity testing indicates that other antibiotics would be ineffective or if oral administration of medication is not possible. d Aminoglycosides are potentially ototoxic and nephrotoxic; do not use in patients with renal dysfunction (see

31 PREVENTION OF SURGICAL COMPLICATIONS (INCLUDING PERITONITIS AND ABSCESSES) Therapeutic approach Perioperative or postoperative antibiotic therapy is not justified. Exceptions: surgery > 90 minutes, orthopaedic procedures involving implants and/or contaminated sites. Pre-surgery considerations Clean surgery <60 minutes without implants Clean surgery min without implants - Clean surgery > 90 min - Cleancontaminated surgery - Clean surgery with implants Contaminateddirty surgery Antibiotics contraindicated Perioperative antibiotics may be indicated considering the risk factors in each case - Perioperative antibiotics indicated - Conflicting evidence for postoperative antibiotics Peri and postoperative antibiotics indicated

32 PREVENTION OF SURGICAL COMPLICATIONS (INCLUDING PERITONITIS AND ABSCESSES) Therapeutic approach Pathogen 1: Staphylococcus pseudintermedius In vitro Tissue sensitivity distribution Amoxicillin + clavulanate Clindamycin Cefalexin / Cefadroxil Marbofloxacin a / Enrofloxacin a,b Cefovecin c Aminoglycosides d Pathogen 2: E. coli and Klebsiella In vitro Tissue sensitivity distribution Amoxicillin / Ampicillin Amoxicillin + clavulanate Cefalexin / Cefadroxil Marbofloxacin a / Enrofloxacin a,b Cefovecin c Aminoglycosides d 3 3 Pathogen 3: Pseudomonas In vitro Tissue sensitivity distribution Marbofloxacin a / Enrofloxacin a,b Aminoglycosides d Ceftazidime 3 3 Pathogen : Enterococcus In vitro Tissue sensitivity distribution Amoxicillin / Ampicillin Amoxicillin + clavulanate Marbofloxacin a / Enrofloxacin a,b 3 3 Pathogen : Anaerobes Amoxicillin / Ampicillin Amoxicillin + clavulanate Metronidazole Pradofloxacin a,e In vitro Tissue sensitivity distribution Treatment choice Treatment choice Treatment choice Treatment choice Treatment choice Sensitivity and distribution 1 = nil 2 = weak 3 = average = good = excellent Treatment choice 1 st line 2 nd line Last resort Excluded for this indication a Avoid use in growing dogs of large breeds. b In cats, use of enrofloxacin has been associated with a risk of retinal toxicity. Do not exceed mg/kg. c Cefovecin is a third generation cephalosporin and therefore a last resort antibiotic. It should only be used if sensitivity testing indicates that other antibiotics would be ineffective or if oral administration of medication is not possible. d Aminoglycosides are potentially ototoxic and nephrotoxic; do not use in patients with renal dysfunction (see education/prevention. html). e Pradofloxacin is a last resort choice due to its very extended spectrum of activity and should only be used if a narrower spectrum antibiotic cannot be used (based on sensitivity testing results).

33 DELICAMENT Ceva s unique solution n Our range of antibiotics is tailored for veterinary use. Our products are available in two and four-way break tablets as well as a liquid clindamycin. The flavoured and chewable tablets have been designed to improve acceptance and compliance. Amoxicillin + clavulanic acid available in 0mg, 62.mg, 20mg, 00mg, 62mg Cefalexin available in 7mg, 300mg and 70mg Clindamycin available in 88mg, 26mg and 2mg oral solution Marbofloxacin available in 10mg, 0mg, 100mg Achieving dosing accuracy over a wide weight range has never been easier. Enrofloxacin available in 1mg, 0mg, 10mg and 200mg

34 n Because antibiotics should only be used when necessary to limit the development of resistance, Ceva has a range of dermatology products for all skin types. A range of shampoos, waterless mousses, pads, spoton and serum to maintain the skin barrier. Chlorehexidine digluconate and miconazole shampoo for dogs available in 200ml and 00ml bottles. Ciclosporin oral solution for dogs. Available in ml, 1ml, 30ml and 0ml bottles. To find out more about our products, please visit ceva.co.uk or contact your territory manager.

35 Kesium chewable tablets for cats and dogs. Active substances: amoxicillin (as amoxicillin trihydrate) and clavulanic acid (as potassium clavulanate). Indications for Use: For the treatment of the following infections caused by ß lactamase producing strains of bacteria sensitive to amoxicillin in combination with clavulanic acid and where clinical experience and/or sensitivity testing indicates the product as the drug of choice. For the treatment of skin infections (including superficial and deep pyodermas) associated with Staphylococcus spp., urinary tract infections associated with Staphylococcus spp., Streptococcus spp., Escherichia coli and Proteus mirabilis, respiratory tract infections associated with Staphylococcus spp., Streptococcus spp. and Pasteurella spp., digestive tract infections associated with Escherichia coli. Infections of the oral cavity (mucous membrane) associated with Pasteurella spp., Streptococcus spp., Escherichia coli. Efex chewable tablets for cats and dogs. Active substance: marbofloxacin. Indications for use: In cats marbofloxacin is indicated in the treatment of skin and soft tissue infections (wounds, abscesses, phlegmons) caused by susceptible strains of organisms. Upper respiratory tract infections caused by susceptible strains of organisms. In dogs marbofloxacin is indicated in the treatment of: skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) caused by susceptible strains of organisms, urinary tract infections (UTI) caused by susceptible strains of organisms associated or not with prostatitis or epididymitis, respiratory tract infections caused by susceptible strains of organisms. Therios palatable tablets for dogs or chewable tablets for cats. Active substance: cefalexin (as cefalexin monohydrate). Indications for use: In cats: Infections caused by bacteria susceptible to cefalexin: Lower urinary tract infections due to Escherichia coli and Proteus mirabilis, treatment of cutaneous and subcutaneous infections: pyoderma due to Staphylococcus spp. and wounds and abscesses due to Pasteurella spp. In dogs: For the treatment of bacterial skin infections in dogs (including deep and superficial pyoderma) caused by organisms sensitive to cefalexin, for the treatment of urinary tract infections in dogs (including nephritis and cystitis) caused by organisms sensitive to cefalexin. XeDen tablets for cats and dogs. Active substance: Enrofloxacin. Indications for use: In cats: treatment of upper respiratory tract infections. In dogs: treatment of lower urinary tract infections (associated or not with prostatitis) and upper urinary tract infections caused by Escherichia coli or Proteus mirabilis, treatment of superficial and deep pyoderma. Zodon chewable tablets for dogs and oral solution for cats and dogs. Active substance: Clindamycin (as hydrochloride). Indications for use: Infections caused by clindamycin sensitive organisms. In cats: For the treatment of infected wounds and abscesses caused by clindamycin sensitive species of Staphylococcu spp. and Streptococcus spp. In dogs: For the treatment of infected wounds, abscesses and oral cavity/dental infections caused by or associated with clindamycin sensitive species of Staphylococcus spp., Streptococcus spp., (except Streptococcus faecalis), Bacteroides spp., Fusobacterium necrophorum, Clostridium perfringens, for the treatment of superficial pyoderma associated with Staphylococcus pseudintermedius, for the treatment of osteomyelitis caused by Staphylococcus aureus. Adaxio Shampoo for dogs. Active substance: Chlorhexidine digluconate 20 mg (equivalent to chlorhexidine mg), miconazole nitrate 20 mg (equivalent to miconazole mg). Indications for use: For the treatment and control of seborrhoeic dermatitis associated with Malassezia pachydermatis and/or Staphylococcus pseudintermedius. Contraindications: Do not use in case of hypersensitivity to the active substances or to any of the excipients. Modulis 100 mg/ml oral solution for dogs. Active Substance: Ciclosporin 100mg/ml. Indications for use: Treatment of chronic manifestations of atopic dermatitis in dogs. Contraindications: Do not use in cases of hypersensitivity to ciclosporin or one of the excipients. Do not use in dogs less than six months of age or less than 2 kg in weight. Do not use in cases with a history of malignant disorders or progressive malignant disorders. Do not vaccinate with a live vaccine during treatment or within a two week interval before or after treatment. For further information on contraindications, side effects, precautions and warnings, please refer to product packaging and leaflet. Further information is available from the SPCs. Use medicines responsibly ( Legal category: POM-V UK POM IE

ROUND TABLE ON ANTIMICROBIAL USE TIME TO CHANGE PARTICIPANTS MODERATOR. As little as possible and only as much as necessary.

ROUND TABLE ON ANTIMICROBIAL USE TIME TO CHANGE PARTICIPANTS MODERATOR. As little as possible and only as much as necessary. ROUND TABLE ON ANTIMICROBIAL USE TIME TO CHANGE Time to change was the topic of the round table presenting the Pan-European consensus on antimicrobial resistance and use, held at the occasion of the congress

More information

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological

More information

Therios 300 mg and 750 mg Palatable Tablets for Dogs

Therios 300 mg and 750 mg Palatable Tablets for Dogs Ceva Animal Health Ltd Telephone: 01494 781510 Website: www.ceva.com Email: cevauk@ceva.com Therios 300 mg and 750 mg Palatable Tablets for Dogs Species: Therapeutic indication: Active ingredient: Product:

More information

ANTIBIOTIC USE GUIDELINES FOR URINARY TRACT AND RESPIRATORY DISEASE

ANTIBIOTIC USE GUIDELINES FOR URINARY TRACT AND RESPIRATORY DISEASE ANTIBIOTIC USE GUIDELINES FOR URINARY TRACT AND RESPIRATORY DISEASE Jane Sykes, BVSc(Hons), PhD, DACVIM (SAIM) School of Veterinary Medicine Dept. of Medicine & Epidemiology University of California Davis,

More information

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),

More information

Københavns Universitet

Københavns Universitet university of copenhagen Københavns Universitet Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats Lappin, M. R.; Blondeau, J.; Boothe, D.; Breitschwerdt, E. B.; Guardabassi,

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH

More information

This document contains guidelines for the treatment

This document contains guidelines for the treatment Guideline and Recommendation J Vet Intern Med 2017;31:279 294 Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International

More information

Pathogens commonly isolated from selected diseases

Pathogens commonly isolated from selected diseases Pathogens commonly isolated from selected diseases Equine pneumonia/pleuropneumonia -hemolytic Strep. Clostridium Pasteurella E. coli Klebsiella pneumoniae Bacteroides Equine enteric pathogens Salmonella

More information

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1 Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director

More information

Copy in the header and footer will not appear on the final printed label LAB0042 Prepared: 28/02/01 SYRINGE LABEL

Copy in the header and footer will not appear on the final printed label LAB0042 Prepared: 28/02/01 SYRINGE LABEL SYRINGE LABEL PRESCRIPTION ANIMAL REMEDY FOR ANIMAL TREATMENT ONLY VibraVet* 100 PASTE For Cats and Dogs 100 mg/g DOXYCYCLINE as monohydrate Infopest Verified Antibiotic READ LEAFLET BEFORE USE 2.5 g 2.0

More information

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active

More information

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OTOMAX EAR DROPS SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the veterinary medicinal product contains:

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection

More information

Veterinary Medicinal Product

Veterinary Medicinal Product Veterinary Medicinal Product CZ, DE, IT, AT, BE, NL, LUX : Kesium 500 mg / 125 mg Chewable tablets for dogs DK, FI, SE: Kesium vet 500 mg / 125 mg Chewable tablets for dogs UK, IE, FR, EL, PL, HU, RO,

More information

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer

More information

Part II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)

Part II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride) Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet

More information

The Bug Stops Here: Treating Resistant Staph Infections Holly Roberts, DVM, MS, DACVD Blue Pearl Veterinary Specialists San Antonio, TX

The Bug Stops Here: Treating Resistant Staph Infections Holly Roberts, DVM, MS, DACVD Blue Pearl Veterinary Specialists San Antonio, TX The Bug Stops Here: Treating Resistant Staph Infections Holly Roberts, DVM, MS, DACVD Blue Pearl Veterinary Specialists San Antonio, TX 1. Staphylococcus bacteria a. Gram positive b. Opportunistic pathogens

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Boflox flavour 20 mg tablets for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:

More information

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats

SUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each

More information

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Marbotab P 20 mg tablets for dogs and cats

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Marbotab P 20 mg tablets for dogs and cats SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbotab P 20 mg tablets for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:

More information

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 500 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 500 mg cephalexin

More information

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 1000 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 1000 mg cephalexin

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

Unshakeable confidence

Unshakeable confidence NEW PRODUCT OF THE YEAR as voted by vets for the 2nd year running** Unshakeable confidence Osurnia is the only otitis externa* treatment that applies like a liquid and stays like a gel. Right where you

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLAVUBACTIN 500/125 MG tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin

More information

CASE REPORTS SKIN INFECTIONS PART 1

CASE REPORTS SKIN INFECTIONS PART 1 CASE REPORTS SKIN INFECTIONS PART 1 CONTENT Case 1 German shepherd with deep pyoderma 04 Dr. Antonella Vercelli, Dr. Luisa Cornegliani Case 2 Lurcher with superficial pyoderma secondary to atopic dermatitis

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance

More information

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015 Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare flavour 80mg tablets for dogs (UK and IE) Marbocare F 80mg tablets for dogs (FR) Odimar 80mg tablets for dogs (BE,

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg

SUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cefaseptin 750 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: cefalexin

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

Guidelines for the clinical use of antimicrobial agents in the treatment of dogs and cats

Guidelines for the clinical use of antimicrobial agents in the treatment of dogs and cats Guidelines for the clinical use of antimicrobial agents in the treatment of dogs and cats Published in September 2018 by The New Zealand Veterinary Association PO Box 11212 Wellington 6142, New Zealand

More information

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEOSPORIN SKIN / ANTIBIOTIC OINTMENT

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEOSPORIN SKIN / ANTIBIOTIC OINTMENT For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEOSPORIN SKIN / ANTIBIOTIC OINTMENT Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ointment / Ophthalmic Ointment

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Routine internal quality control as recommended by EUCAST Version 3.1, valid from Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus

More information

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,

More information

22/09/2010. Laboratory 2a + b Staphylococci and Streptococci

22/09/2010. Laboratory 2a + b Staphylococci and Streptococci Laboratory 2a + b Staphylococci and Streptococci 1 Hamster: To be or not to be..!? (a play on Ham-let!) Summary on Exercise 1 (Lab 2a) Big colony heavy growth, color? Double-zone hly CAT and Tube Coag

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

Health Products Regulatory Authority

Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin

More information

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE

More information

Simplicef is Used to Treat Animals with Skin Infections

Simplicef is Used to Treat Animals with Skin Infections Simplicef is Used to Treat Animals with Skin Infections PRODUCT INFO Simplicef tablets are a semi-synthetic cephalosporin antibiotic cefpodoxime proxetil used to cure infections caused by the susceptible

More information

Diabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals

Diabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals Diabetic Foot Infection Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals History of previous amputation [odds ratio (OR)=19.9, P=.01], Peripheral vascular disease (OR=5.5, P=.007)

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Malaseb shampoo for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active substances: Chlorhexidine

More information

Step 1. Unique Considerations. Goals. A Pattern Approach. Provide a real life perspective Discuss problems. Feline Otitis.

Step 1. Unique Considerations. Goals. A Pattern Approach. Provide a real life perspective Discuss problems. Feline Otitis. PetsLivingLonger.com Keith A Hnilica DVM, MS, MBA Diplomate ACVD Bigdog@itchnot.com (865) 405-4203 Goals Provide a real life perspective Discuss problems Discuss an efficient plan Review feline otitis

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,

More information

Responsible use of antibiotics

Responsible use of antibiotics Responsible use of antibiotics Uga Dumpis MD, PhD Department of Infectious Diseases and Infection Control Pauls Stradiņs Clinical University Hospital Challenges in the hospitals Antibiotics are still effective

More information

Cellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018

Cellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018 Cellulitis Assoc Prof Mark Thomas Conference for General Practice Auckland Saturday 28 July 2018 Summary Cellulitis Usual treatment flucloxacillin for 5 days Frequent recurrences consider penicillin 250mg

More information

Cipro for klebsiella uti

Cipro for klebsiella uti Cipro for klebsiella uti Search Can UTI be an effective treatment for Klebsiella Pneumoniae? It is safe or dangerous to use UTI while suffering from Klebsiella Pneumoniae? 87 discussions on Treato. instock

More information

Advanced Practice Education Associates. Antibiotics

Advanced Practice Education Associates. Antibiotics Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright

More information

Antimicrobial Selection and Therapy for Equine Musculoskeletal Trauma

Antimicrobial Selection and Therapy for Equine Musculoskeletal Trauma Antimicrobial Selection and Therapy for Equine Musculoskeletal Trauma Lucio Petrizzi DVM DECVS Università degli Studi di Teramo Surgical site infections (SSI) Microbial contamination unavoidable Infection

More information

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck! Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which

More information

Do clinical microbiology laboratory data distort the picture of antibiotic resistance in humans and domestic animals?

Do clinical microbiology laboratory data distort the picture of antibiotic resistance in humans and domestic animals? Do clinical microbiology laboratory data distort the picture of antibiotic resistance in humans and domestic animals? Scott Weissman, MD 2 June 2018 scott.weissman@seattlechildrens.org Disclosures I have

More information

UTI Dr S Mathijs Department of Pharmacology

UTI Dr S Mathijs Department of Pharmacology UTI Dr S Mathijs Department of Pharmacology Introduction Responsible for > 7 million consultations annually 15% of all antibiotic prescriptions 40% of all hospital acquired infections Significant burden

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline

More information

Rational management of community acquired infections

Rational management of community acquired infections Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?

More information

APPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.

APPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base. APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAMEAND DOSAGE FORM: DALACIN C TM 150 mg (Capsules) COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin

More information

EUCAST recommended strains for internal quality control

EUCAST recommended strains for internal quality control EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

gingivitis: periodontitis: dental caries: palatinitis: oral pharyngitis and tonsillitis: mouth abscess: glossitis: oro-sinus fistula: gingivitis:

gingivitis: periodontitis: dental caries: palatinitis: oral pharyngitis and tonsillitis: mouth abscess: glossitis: oro-sinus fistula:  gingivitis: ABSTRACT Mouth is one of the anatomical segments of the digestive microbiota which is characterized by a marked diversity. Among the multitude of microorganisms that inhabit the oral mucosa at a time,

More information

General Rules Topicals for Skin Infections Topicals for Allergic Skin Disease Topicals for Seborrhea

General Rules Topicals for Skin Infections Topicals for Allergic Skin Disease Topicals for Seborrhea Douglas J. DeBoer, D.V.M., Diplomate A.C.V.D. School of Veterinary Medicine University of Wisconsin-Madison General Rules Topicals for Skin Infections Topicals for Allergic Skin Disease Topicals for Seborrhea

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS La Haute Marche Javené BP FOUGERES cedex FRANCE

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS La Haute Marche Javené BP FOUGERES cedex FRANCE FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS La Haute Marche Javené BP 90203 35302 FOUGERES cedex FRANCE DECENTRALISED PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT Zodon 25 mg/ml oral solution for cats

More information

Amoxicillin clavulanic acid spectrum

Amoxicillin clavulanic acid spectrum Cari untuk: Cari Cari Amoxicillin clavulanic acid spectrum 14-8-2017 Amoxicillin and clavulanate potassium (AMC), also known as augmentin, is an antibiotic used to treat bacterial infections. AMC is available

More information

DECHRA DERMATOLOGY. Why Dechra Dermatology?

DECHRA DERMATOLOGY. Why Dechra Dermatology? DECHRA DERMATOLOGY Why Dechra Dermatology? Veterinarians premier choice in Dermatology, Dechra Veterinary Products offers branded solutions for your dermatology needs. TRUSTED INGREDIENTS Dechra s topical

More information

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses

More information

Microbiology ( Bacteriology) sheet # 7

Microbiology ( Bacteriology) sheet # 7 Microbiology ( Bacteriology) sheet # 7 Revision of last lecture : Each type of antimicrobial drug normally targets a specific structure or component of the bacterial cell eg:( cell wall, cell membrane,

More information

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Card box and package leaflet for brown glass bottle (Type 1) 1. NAME OF THE

More information

Indian Journal of Canine Practice Volume 6 Issue 2, December, 2014

Indian Journal of Canine Practice Volume 6 Issue 2, December, 2014 THERAPEUTIC TRIALS OF PYODERMA IN DOGS WITH CLINDAMYCIN AND IN COMBINATION WITH A TOPICAL ANTIBACTERIAL COMBINATION OF CHLORHEXIDINE GLUCONATE AND SILVER SULPHADIAZENE M.A. Kshama¹ and S.Yathiraj² ¹Assistant

More information

Treatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals

Treatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals Treatment of Surgical Site Infection Meeting Quality Statement 6 Prof Peter Wilson University College London Hospitals TEG Quality Standard 6 Treatment and effective antibiotic prescribing: People with

More information

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers

More information

Cipro for gram positive cocci in urine

Cipro for gram positive cocci in urine Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar

More information

number Done by Corrected by Doctor Dr.Malik

number Done by Corrected by Doctor Dr.Malik number 27 Done by Fatimah Farhan Corrected by Basil Al-Bakri Doctor Dr.Malik Note: anything in red is just extra info and you will not be asked about it in the exam. In this sheet we will continue talking

More information

I ve tried X, Y & Z Why is nothing working? Common Reasons for Dermatologic Treatment Failures. Charlie Pye BSc, DVM, DVSc, Diplomate ACVD

I ve tried X, Y & Z Why is nothing working? Common Reasons for Dermatologic Treatment Failures. Charlie Pye BSc, DVM, DVSc, Diplomate ACVD + I ve tried X, Y & Z Why is nothing working? Common Reasons for Dermatologic Treatment Failures Charlie Pye BSc, DVM, DVSc, Diplomate ACVD + Overview Frustrating when treatment does not improve condition

More information

Unique, fast-acting, and long-lasting injectables for livestock health & nutrition

Unique, fast-acting, and long-lasting injectables for livestock health & nutrition Injection Catalogue OK.indd 3 10/27/16 6:34 PM Fertizone (M) Sdn. Bhd. Injectable Products MECTINZONE 1% MECTINZONE 2% FLORVET DEXAZON OXYZONE20 LA OXYZONE30 LA SULFAZONE TILMIZONE TYLOZONE20 ENROXIN10

More information

Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance

Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance 22nd Congress of the EAHP "Hospital pharmacists catalysts for change", 22-24 March 2017, Cannes Disclosure

More information

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,

More information

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient 1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Synuclav 250 mg Tablets for Dogs (UK) Clavobay 250 mg Tablets for Dogs (BE, FR, IS, IT, PT) Clavubay 250mg Tablets for Dogs

More information

ANTIBIOTICS COLIPHyL A.U.V. 8

ANTIBIOTICS COLIPHyL A.U.V. 8 Coliphyl A.U.V. 8 Coliphyl premix for pigs A.U.V. Active Ingredient : Colistin sulfat 120 g Target species: Swine Indications for use: Treatment of colistin sensitive intestinal infections caused by Salmonella

More information

Acute Pyelonephritis POAC Guideline

Acute Pyelonephritis POAC Guideline Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Clavudale

More information

Copyright 2012 Diabetes In Control, Inc. For permission to reprint, please contact Heather Moran, Production Editor, at

Copyright 2012 Diabetes In Control, Inc. For permission to reprint, please contact Heather Moran, Production Editor, at Malignant Otitis Externa Inflammation and damage at the base of the skull due to an untreated outer ear P. aeruginosa most common organism Yellow-green drainage from the ear Odor Fever Deep inner ear pain

More information

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information